detect an active
infection in a
Influenza A +
Order a Test
Our Range of Services
911OccMed is the all-in-one solution
for all of your pre-employment needs.
All 911OccMed technicians at our locations are certified and trained in accordance with 49CFR (Part 40) procedures for Transportation Workplace, Drug and Alcohol Testing Programs. The federal requirements of Part 40 ensure best practices and establish standards for training both urine collection and breath alcohol technicians within the industry.
911OccMed corporate staff includes credentialed professionals, bringing the highest standards of training to 911OccMed and its client base.
911OccMed is affiliated with numerous labs throughout the U.S., helping us establish a network of over 20,000 collection sites across the country. Our comprehensive services are built around a passion for reducing drug abuse as well as empowering individuals and companies to manage their health and wellness through affordable lab screening.
We strive to provide our customers with the highest quality service. All the time.
Patients may be able to receive reimbursement from their health insurance company for all or a portion of their COVID-19 test. Please contact your insurance company for additional information as to whether you may be eligible to receive reimbursement for your COVID-19 test and how to apply.
All tests offered or made available at 911OccMed and collection sites are performed by CLIA certified labs and have received an Emergency Use Authorization from the FDA. For more information on what this means, please click the links associated with each test and review the information included in the patient consent form.
Rapid Antigen COVID-19 Test
Rapid Results – as fast as 10 minutes, see your location’s website for details. Can be collected by nasal mid-turbinate or nasopharyngeal swab. One of the following tests will be utilized for the Rapid Antigen COVID-19 Test:
Carestart (Tempe, Chandler)
Quidel Sofia2 SARS-CoV-2 Assay (Mesa, Glendale)
All of 911OccMed’s antigen test offerings utilize tests that have received emergency use authorization from the FDA.
See individual fact sheets and test information above for specifics.
Rapid COVID-19 IgG/IgM Antibody Test
Assure COVID-19 IgG/IgM Rapid Test Device
- IgG: This is the most common antibody. It’s in blood and other body fluids, and protects against bacterial and viral infections. IgG can take time to form after an infection or immunization.
- IgM: Found mainly in blood and lymph fluid, this is the first antibody the body makes when it fights a new infection.
The Assure COVID-19 IgG/IgM Rapid Test Device, a test for the qualitative detection and differentiation of IgM and IgG antibodies to SARS-CoV-2 (often referred to as COVID-19 or the novel coronavirus) in human venous whole blood (sodium EDTA), serum, plasma (sodium EDTA) and fingerstick whole blood.
The Assure COVID-19 IgG/IgM Rapid Test Device is intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection. At this time, it is unknown for how long antibodies persist following infection and if the presence of antibodies confers protective immunity.
September 23, 2020 and the FDA guidance, “Policy for Diagnostic Tests for Coronavirus Disease-2019 during the Public Health Emergency” issued on March 16, 2020 (updated May 11, 2020). The
- FDA issued this guidance to help accelerate the availability of novel coronavirus (COVID-19) tests developed by laboratories and commercial manufacturers during the public health emergency. This test has not been FDA cleared or approved; this test has been authorized by FDA under an EUA for use by laboratories certified under CLIA, that meet requirements to perform waived, moderate or high complexity test.
- This test has been authorized only for the presence of IgM and IgG antibodies against SARS-CoV-2, not for any other viruses or pathogens.
- This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
- Negative results do not preclude SARS-CoV-2 infection and should not be used as the sole basis for patient management decisions. The sensitivity of the EcoTest COVID-19 IgG/IgM Rapid Test Device early after infection is unknown. If acute infection is suspected, direct testing for SARS-CoV-2 is necessary.
- Results from antibody testing should not be used as the sole basis to diagnose or exclude SARS-CoV-2 infection or to inform infection status.
- Positive results may be due to past or present infection with non-SARS-CoV-2 coronavirus strains, such as coronavirus HKU1, NL63, OC43, or 229E.
COVID-19 Antigen + Flu Combo Test
Three tests in one! This test is recommended for all individuals and especially those with symptoms.
Tests for COVID-19, Influenza A, and Influenza B
Results are generally reported within 60 minutes.
Covid Clinic is offering the Quidel Corporation Sofia 2 FLU + SARS Antigen FIA Test. This test has received an emergency use authorization from the FDA.
The specimen is collected by a nasal swab. The cotton swab does not need to be inserted far into the nose and is rotated in a circle around the entire inside edge of each nostril at least three times. Results are generally available within 60 minutes although result time may vary from location to location.
Expedited RT-PCR COVID-19 Test
- Results are generally reported within two hours.
- Satisfies most travel restriction requirements.
- Collected by anterior nares nasal swab (front of the nose only).
The Rapid RT-PCR COVID-19 Test is a molecular, in vitro diagnostic test utilizing end point reverse transcriptase polymerase chain reaction (RT-PCR) and lateral flow technologies for the qualitative, visual detection of the coronavirus SARS-CoV-2 viral RNA. The four steps utilized to perform the test are lysis of the virus, reverse transcription of viral RNA to cDNA, nucleic acid amplification, and detection.
The Rapid RT-PCR COVID-19 Test has been released under FDA Emergency Use Authorization (EUA) for the detection of nucleic acid from SARS-CoV-2 (the virus responsible for COVID-19 infection), and can be used in applications that require molecular/ RT-PCR testing. Please consult your state health department for additional information regarding specific uses (such as pre and post travel requirements). Many travel restrictions require a RT-PRC, molecular, or NAAT test be conducted prior to arrival at the destination. The Rapid RT-PCR COVID-19 test satisfies most travel requirements; however, it is the purchaser’s responsibility to verify the test will be accepted for travel prior to purchase.